ASX - By Stock
|
PAA |
Re:
Ann: Stable Patient in MND trial reaches 6-months on MPL
|
|
kpax
|
70 |
16K |
23 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
70
|
16K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Stable Patient in MND trial reaches 6-months on MPL
|
|
kpax
|
70 |
16K |
24 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
70
|
16K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Interim analysis recommended in MND trial
|
|
kpax
|
71 |
19K |
22 |
23/03/23 |
23/03/23 |
ASX - By Stock
|
71
|
19K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Investor Webinar Presentation
|
|
kpax
|
92 |
19K |
5 |
17/03/23 |
17/03/23 |
ASX - By Stock
|
92
|
19K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Cancer Trial Update
|
|
kpax
|
220 |
43K |
20 |
10/03/23 |
10/03/23 |
ASX - By Stock
|
220
|
43K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Cancer Trial Update
|
|
kpax
|
220 |
43K |
10 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
220
|
43K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Cancer Trial Update
|
|
kpax
|
220 |
43K |
10 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
220
|
43K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Cancer Trial Update
|
|
kpax
|
220 |
43K |
17 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
220
|
43K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Cancer Trial Update
|
|
kpax
|
220 |
43K |
17 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
220
|
43K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Cancer Trial Update
|
|
kpax
|
220 |
43K |
20 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
220
|
43K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Interim analysis recommended in MND trial
|
|
kpax
|
71 |
19K |
35 |
02/03/23 |
02/03/23 |
ASX - By Stock
|
71
|
19K
|
35
|
|
ASX - By Stock
|
PAA |
Re:
Ann: European Patent relating to MPL Combinations in Cancer
|
|
kpax
|
6 |
2.9K |
32 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
6
|
2.9K
|
32
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient of Cohort 2 Dosed in MND Trial
|
|
kpax
|
79 |
19K |
13 |
23/02/23 |
23/02/23 |
ASX - By Stock
|
79
|
19K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient of Cohort 2 Dosed in MND Trial
|
|
kpax
|
79 |
19K |
28 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
79
|
19K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Bella's Monepantel Trial
|
|
kpax
|
127 |
28K |
33 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
127
|
28K
|
33
|
|
ASX - By Stock
|
PAA |
Re:
Interactive AGM Yes/No vote
|
|
kpax
|
87 |
13K |
11 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
87
|
13K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Interactive AGM Yes/No vote
|
|
kpax
|
87 |
13K |
17 |
16/02/23 |
16/02/23 |
ASX - By Stock
|
87
|
13K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Interactive AGM Yes/No vote
|
|
kpax
|
87 |
13K |
8 |
15/02/23 |
15/02/23 |
ASX - By Stock
|
87
|
13K
|
8
|
|
ASX - By Stock
|
PAA |
Interactive AGM Yes/No vote
|
|
kpax
|
87 |
13K |
17 |
15/02/23 |
15/02/23 |
ASX - By Stock
|
87
|
13K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Progresses to Elevated Doses in MND Patients
|
|
kpax
|
79 |
18K |
25 |
14/02/23 |
14/02/23 |
ASX - By Stock
|
79
|
18K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust canine trial update
|
|
kpax
|
51 |
12K |
36 |
10/02/23 |
10/02/23 |
ASX - By Stock
|
51
|
12K
|
36
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust canine trial update
|
|
kpax
|
51 |
12K |
5 |
10/02/23 |
10/02/23 |
ASX - By Stock
|
51
|
12K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust canine trial update
|
|
kpax
|
51 |
12K |
19 |
10/02/23 |
10/02/23 |
ASX - By Stock
|
51
|
12K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust canine trial update
|
|
kpax
|
51 |
12K |
34 |
10/02/23 |
10/02/23 |
ASX - By Stock
|
51
|
12K
|
34
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
kpax
|
61 |
14K |
5 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
61
|
14K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
kpax
|
61 |
14K |
9 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
61
|
14K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
MND PK PD data and why it influences the upcoming Covid-19 trial
|
|
kpax
|
40 |
9.5K |
23 |
21/01/23 |
21/01/23 |
ASX - By Stock
|
40
|
9.5K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
MND PK PD data and why it influences the upcoming Covid-19 trial
|
|
kpax
|
40 |
9.5K |
9 |
20/01/23 |
20/01/23 |
ASX - By Stock
|
40
|
9.5K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
MND PK PD data and why it influences the upcoming Covid-19 trial
|
|
kpax
|
40 |
9.5K |
24 |
20/01/23 |
20/01/23 |
ASX - By Stock
|
40
|
9.5K
|
24
|
|
ASX - By Stock
|
PAA |
MND PK PD data and why it influences the upcoming Covid-19 trial
|
|
kpax
|
40 |
9.5K |
38 |
20/01/23 |
20/01/23 |
ASX - By Stock
|
40
|
9.5K
|
38
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Successfully Completes First Patient Cohort
|
|
kpax
|
164 |
40K |
13 |
16/01/23 |
16/01/23 |
ASX - By Stock
|
164
|
40K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Canine Trial Update clarification
|
|
kpax
|
97 |
22K |
12 |
13/01/23 |
13/01/23 |
ASX - By Stock
|
97
|
22K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
2023 , MND, K9 Cancer Commercial Deal , Covid , Human Cancer, OHD
|
|
kpax
|
153 |
42K |
13 |
14/12/22 |
14/12/22 |
ASX - By Stock
|
153
|
42K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient Dosed in MND Phase 1/2 Trial
|
|
kpax
|
171 |
44K |
16 |
18/11/22 |
18/11/22 |
ASX - By Stock
|
171
|
44K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient Dosed in MND Phase 1/2 Trial
|
|
kpax
|
171 |
44K |
17 |
18/11/22 |
18/11/22 |
ASX - By Stock
|
171
|
44K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient Dosed in MND Phase 1/2 Trial
|
|
kpax
|
171 |
44K |
19 |
17/11/22 |
17/11/22 |
ASX - By Stock
|
171
|
44K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient Dosed in MND Phase 1/2 Trial
|
|
kpax
|
171 |
44K |
27 |
16/11/22 |
16/11/22 |
ASX - By Stock
|
171
|
44K
|
27
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient Dosed in MND Phase 1/2 Trial
|
|
kpax
|
171 |
44K |
15 |
15/11/22 |
15/11/22 |
ASX - By Stock
|
171
|
44K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient Dosed in MND Phase 1/2 Trial
|
|
kpax
|
171 |
44K |
21 |
14/11/22 |
14/11/22 |
ASX - By Stock
|
171
|
44K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient Dosed in MND Phase 1/2 Trial
|
|
kpax
|
171 |
44K |
11 |
14/11/22 |
14/11/22 |
ASX - By Stock
|
171
|
44K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
PAA Post AGM ,, 2022 Highlights
|
|
kpax
|
207 |
48K |
20 |
14/11/22 |
14/11/22 |
ASX - By Stock
|
207
|
48K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: AGM Presentation
|
|
kpax
|
54 |
9.9K |
19 |
10/11/22 |
10/11/22 |
ASX - By Stock
|
54
|
9.9K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: AGM Presentation
|
|
kpax
|
54 |
9.9K |
6 |
10/11/22 |
10/11/22 |
ASX - By Stock
|
54
|
9.9K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: AGM Presentation
|
|
kpax
|
54 |
9.9K |
5 |
10/11/22 |
10/11/22 |
ASX - By Stock
|
54
|
9.9K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: AGM Presentation
|
|
kpax
|
54 |
9.9K |
12 |
10/11/22 |
10/11/22 |
ASX - By Stock
|
54
|
9.9K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: AGM Presentation
|
|
kpax
|
54 |
9.9K |
7 |
10/11/22 |
10/11/22 |
ASX - By Stock
|
54
|
9.9K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
AGM Questions 2022
|
|
kpax
|
78 |
17K |
5 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
78
|
17K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor Webinar
|
|
kpax
|
42 |
7.9K |
14 |
05/11/22 |
05/11/22 |
ASX - By Stock
|
42
|
7.9K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
2022 Moving Toward 2023
|
|
kpax
|
92 |
20K |
16 |
05/11/22 |
05/11/22 |
ASX - By Stock
|
92
|
20K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
2022 Moving Toward 2023
|
|
kpax
|
92 |
20K |
26 |
05/11/22 |
05/11/22 |
ASX - By Stock
|
92
|
20K
|
26
|
|